ASX health stocks broke their losing streak this week, while it was a big week for Nanosonics, Neurizon and Sigma.

The company said is on track for doubling production capacity to 520,000 tonnes of lithium concentrate, starting in 2026.

Worries are building about a potentially toxic mix of worsening inflation and a US economy slowing because of households ...

When the flurry finished, $20.3 billion worth of shares changed hands – the ASX’s second-biggest day ever by value of shares ...

ASX health stocks fall 3.65% over past week, while the broader market is down 2.04% Morgans anlayst Scott Power said there's a risk-off sentiment among investors with concerns about US tariffs Sigma ...

Sigma Healthcare Ltd (ASX: SIG) shares are catching the eye on Thursday after delivering a very strong full year ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Sigma Healthcare Limited (SIG). However, you won't necessarily see their names in the company’s ...

Leader in obstructive sleep apnoea and other sleep-related respiratory disorders ResMed (ASX:RMD) has bucked the trend, up ~21% in the past year. Power’s Powerplay: Sigma enters S&P/ASX 50 ...

Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.